Alzheimer’s patients: A surprise finding in executive function

submitted by: nsf
Deborah Zaitchik says executive function measures for Alzheimer’s patients show staggering declines. Under a National Science Foundation-funded INSPIRE project, Harvard University psychologists Susan Carey and Deborah Zaitchik are studying how executive function influences the process of learning. Here, Zaitchik discusses differences between populations with strong and weak executive function. For more information visit:...

Dietary patterns and risk of dementia in an elderly Japanese population: the Hisayama Study

submitted by: Mio
ABSTRACT Background: To our knowledge, there are no previous reports that assessed the association between dietary patterns and risk of dementia in Asian populations. Objective: We investigated dietary patterns and their potential association with risk of incident dementia in a general Japanese population. Design: A total of 1006 community-dwelling Japanese subjects without dementia, aged 60–79 y, were followed up for a median of 15 y. The reduced rank regression procedure was used to...
Authors: Mio Ozawa, Toshiharu Ninomiya, Tomoyuki Ohara, Yasufumi Doi, Kazuhiro Uchida, Tomoko Shirota, Koji Yonemoto, Takanari Kitazono, Yutaka Kiyohara

The Evolution of Beta Amyloid Cleaving Enzyme (BACE1): an Alzheimer’s Disease Drug Target

submitted by: cdsouthan
Plaque formation in Alzheimer's Disease (AD) is seeded by excision products of Amyloid precursor protein (APP) generated by the combined activities of beta and gamma secretases. To reduce the production of these neurotoxic peptides the inhibition of beta-secretase (Beta-site APP Cleaving Enzyme, BACE1, Swiss-Prot P56817) is being intensively pursued as a possible therapy for AD and all drug candidates are screened for selectivity against the paralogue (BACE2, Swiss-Prot Q9Y5Z0) which...

Cytokines and Neutrophins in Neuroprotection

submitted by: alex01
Dr. Michael Spedding published recently a review on the role of cytokines and neurotrophins in disease. Neurotrophins (e.g. BDNF) have beneficial effects on neuronal plasticity and brain metabolism. Inflammatory cytokines (e.g. IL1beta)oppose the effects of neurotrophins. Both, neurotrophins and cytokines are targets for the development of new drugs affecting central nervous system. Brain-derived neurotrophic factor (BDNF) is the main activity-dependent neurotrophic factor. Interleukin 1beta...

TGFß & Alzheimer's Disease

submitted by: alex01

R.A. Flavell (Yale University, New Haven, CT) discusses the role of Transforming Growth Factor ß (TGFß) in disease. In the central nervous system of a murine model of AD this cytokine appears to prevent macrophages from attacking ß-amyloid. Flavell visualizes that selective blockade of this TGFß
activity could lead to the destruction of plaques in patients with AD.

Alzheimer's Disease

submitted by: alex01
Z. Khachaturian, PhD. - New approaches to the therapy of Alzheimer’s disease (AD) are discussed in video interviews of this series. According to Z. Khachaturian (Potomac, MD) substantial progress has been made during the last 10 years in our understanding of pathogenesis of Alzheimer’s disease as well as in the discovery of biomarkers and therapeutic approaches. In addition to cholinergic drugs, inhibitors of plaque formation have been discovered, but the currently available...

Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.